×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AUPH – aurinia pharmaceuticals inc - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AUPH
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/30
08:25 am
auph
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right [Yahoo! Finance]
Medium
Report
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right [Yahoo! Finance]
3/30
08:00 am
auph
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
Medium
Report
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
3/29
02:28 am
auph
Does Aurinia's Tang-Led Leadership Overhaul Reshape the Bull Case for Aurinia Pharmaceuticals (AUPH)? [Yahoo! Finance]
Low
Report
Does Aurinia's Tang-Led Leadership Overhaul Reshape the Bull Case for Aurinia Pharmaceuticals (AUPH)? [Yahoo! Finance]
3/27
04:18 pm
auph
Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance [Seeking Alpha]
Low
Report
Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance [Seeking Alpha]
3/23
11:46 am
auph
MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition [Yahoo! Finance]
Low
Report
MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition [Yahoo! Finance]
3/23
11:00 am
auph
MKT Capital Applauds Aurinia Pharmaceuticals’ Management Transition
Low
Report
MKT Capital Applauds Aurinia Pharmaceuticals’ Management Transition
3/23
08:00 am
auph
Aurinia Announces Management Transition
Low
Report
Aurinia Announces Management Transition
3/15
06:51 pm
auph
Is Aurinia Pharmaceuticals (AUPH) Pricing Reflect Long Term Value After 71% One Year Gain [Yahoo! Finance]
Low
Report
Is Aurinia Pharmaceuticals (AUPH) Pricing Reflect Long Term Value After 71% One Year Gain [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/26/2026
06:00 am
auph
aurinia pharmaceuticals inc - common shares
BEAT
Report
-2.3%
aurinia pharmaceuticals inc - common shares
11/4/2025
06:00 am
auph
aurinia pharmaceuticals inc - common shares
BEAT
Report
5.7%
aurinia pharmaceuticals inc - common shares
7/31/2025
06:00 am
auph
aurinia pharmaceuticals inc - common shares
MISS
Report
-2.6%
aurinia pharmaceuticals inc - common shares
5/12/2025
06:00 am
auph
aurinia pharmaceuticals inc - common shares
BEAT
Report
-5.1%
aurinia pharmaceuticals inc - common shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/3
04:58 pm
auph
Form 8-K Aurinia Pharmaceuticals For: Mar 30
Low
Report
Form 8-K Aurinia Pharmaceuticals For: Mar 30
4/2
04:20 pm
auph
Form 3 Aurinia Pharmaceuticals For: Mar 23 Filed by: Cole Ryan
Low
Report
Form 3 Aurinia Pharmaceuticals For: Mar 23 Filed by: Cole Ryan
4/2
04:19 pm
auph
Form 3 Aurinia Pharmaceuticals For: Mar 23 Filed by: Hearne Michael S
Low
Report
Form 3 Aurinia Pharmaceuticals For: Mar 23 Filed by: Hearne Michael S
3/25
04:15 pm
auph
Form SCHEDULE 13D/A Aurinia Pharmaceuticals Filed by: TANG CAPITAL MANAGEMENT LLC
Low
Report
Form SCHEDULE 13D/A Aurinia Pharmaceuticals Filed by: TANG CAPITAL MANAGEMENT LLC
3/23
08:04 am
auph
Form 8-K Aurinia Pharmaceuticals For: Mar 20
Medium
Report
Form 8-K Aurinia Pharmaceuticals For: Mar 20
3/10
04:26 pm
auph
Form 4 Aurinia Pharmaceuticals For: Mar 06 Filed by: Keenan Greg
Low
Report
Form 4 Aurinia Pharmaceuticals For: Mar 06 Filed by: Keenan Greg
3/3
05:35 pm
auph
Form 4 Aurinia Pharmaceuticals For: Feb 27 Filed by: TANG KEVIN
Medium
Report
Form 4 Aurinia Pharmaceuticals For: Feb 27 Filed by: TANG KEVIN
3/3
05:30 pm
auph
Form SCHEDULE 13D/A Aurinia Pharmaceuticals Filed by: TANG CAPITAL MANAGEMENT LLC
Medium
Report
Form SCHEDULE 13D/A Aurinia Pharmaceuticals Filed by: TANG CAPITAL MANAGEMENT LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/9
Form SC 13D/A Aurinia Pharmaceuticals Filed by: ILJIN SNT Co., Ltd.
13.5%
12/10 Form 6-K Aurinia Pharmaceuticals For: Dec 10 11.7%
9/9 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is now covered by analysts at Citigroup Inc. They set an "outperform" rating and a $14.00 price target on the stock. 10.3%
11/28 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.8%
12/3 Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference 7.1%
3/19 Form 6-K Aurinia Pharmaceuticals For: Mar 18 6.4%
10/15 Does The Aurinia Pharmaceuticals Inc. (TSE:AUP) Share Price Fall With The Market? [Yahoo! Finance News] 6.1%
4/20 Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors 5.4%
12/4 Form 6-K Aurinia Pharmaceuticals For: Dec 03 4.9%
12/10 Form SC 13D/A Aurinia Pharmaceuticals Filed by: ILJIN SNT Co., Ltd. 4.6%
12/10 Form 6-K Aurinia Pharmaceuticals For: Dec 10 11.7%
9/9 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is now covered by analysts at Citigroup Inc. They set an "outperform" rating and a $14.00 price target on the stock. 10.3%
11/28 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.8%
12/3 Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference 7.1%
3/19 Form 6-K Aurinia Pharmaceuticals For: Mar 18 6.4%
10/15 Does The Aurinia Pharmaceuticals Inc. (TSE:AUP) Share Price Fall With The Market? [Yahoo! Finance News] 6.1%
4/20 Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors 5.4%
12/4 Form 6-K Aurinia Pharmaceuticals For: Dec 03 4.9%
12/10 Form SC 13D/A Aurinia Pharmaceuticals Filed by: ILJIN SNT Co., Ltd. 4.6%
TOP News Decliners
10/10
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating.
-13.4%
3/16 Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis -12.3%
3/5 Aurinia Pharmaceuticals' (AUPH) CEO Peter Greenleaf on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -10.4%
3/11 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -8.3%
3/12 Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative -6.7%
8/6 Aurinia Pharmaceuticals, Inc.'s (AUPH) CEO Peter Greenleaf on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.6%
2/22 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.3%
3/17 Form 6-K Aurinia Pharmaceuticals For: Mar 17 -5.5%
2/25 Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team -5.4%
12/2 Aurinia Pharmaceuticals Inc.'s (TSE:AUP) Shift From Loss To Profit [Yahoo! Finance News] -5.3%
3/16 Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis -12.3%
3/5 Aurinia Pharmaceuticals' (AUPH) CEO Peter Greenleaf on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -10.4%
3/11 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -8.3%
3/12 Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative -6.7%
8/6 Aurinia Pharmaceuticals, Inc.'s (AUPH) CEO Peter Greenleaf on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.6%
2/22 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.3%
3/17 Form 6-K Aurinia Pharmaceuticals For: Mar 17 -5.5%
2/25 Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team -5.4%
12/2 Aurinia Pharmaceuticals Inc.'s (TSE:AUP) Shift From Loss To Profit [Yahoo! Finance News] -5.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: